This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
Javier L. Munoz, MD, MS, FACP
Advertisement
Articles by Javier L. Munoz, MD, MS, FACP
Javier L. Munoz, MD, MS, FACP, discusses how the sequencing of therapies has changed in the last year.
An expert in relapsed/refractory follicular lymphoma discusses the approval of tazemetostat as a treatment and reviews the phase 2 clinical trial data.
Javier L. Munoz, MD, MS, FACP, describes the current third-line treatment options available for relapsed/refractory follicular lymphoma.
A specialist explains the factors considered when it comes to choosing treatments for patients with relapsed/refractory follicular lymphoma, and the clinical endpoints to look for.
Javier L. Munoz, MD, MS, FACP, describes the effects of R/R FL and discusses the current treatment options available.
Advertisement
Latest Updated Articles
OncView™ Podcast: Updates in Therapies for Relapsed/Refractory Follicular LymphomaPublished: August 29th 2021 | Updated:
Changes in Sequencing of R/R FL TherapiesPublished: July 20th 2021 | Updated:
- Use of Tazemetostat for R/R FL
Published: July 13th 2021 | Updated:
- Treatment Options for Third Line R/R FL
Published: July 13th 2021 | Updated:
- Factors in Choosing Relapsed/Refractory Follicular Lymphoma Treatments
Published: July 6th 2021 | Updated:
- Current Treatment Options for Relapsed/Refractory Follicular Lymphoma
Published: July 6th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
4
Examining the Full Scope of Future Advancements in Radiation Oncology
5
